E2F3 and neuroblastoma: Genomic studies have demonstrated that tumors that amplify E2F3 often also acquire mutations in RB1 with consequent inactivation of the RB pathway [41], but we did not find any association between RB1 gene expression in stage 4S NB patients and clinical outcome.